JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Home・Akcijų sąrašas・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

21.79 -4.72

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.43

Max

22.77

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-14M -50M
Pardavimai	12M 128M
Pelno marža	-39.506
Darbuotojai	1,784
EBITDA	-17M -48M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+54.22% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	642M 2.9B
Ankstesnė atidarymo kaina	26.51
Ankstesnė uždarymo kaina	21.79

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

28.13 / 31.12 Palaikymas ir pasipriešinimas

Zai Lab Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-23 23:47; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

2026-04-23 23:43; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-23 23:43; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-23 23:43; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

2026-04-23 23:13; UTC

Įsigijimai, susijungimai, perėmimai

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

2026-04-23 22:33; UTC

Uždarbis

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

2026-04-23 22:17; UTC

Uždarbis

PLS Executed Offtake Agreement With Ronbay

2026-04-23 22:17; UTC

Uždarbis

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

2026-04-23 22:16; UTC

Uždarbis

PLS Commences Commissioning of Midstream Demonstration Plant

2026-04-23 22:15; UTC

Uždarbis

PLS Group Reaffirms FY26 Guidance for All Metrics

2026-04-23 22:14; UTC

Uždarbis

PLS Group 3Q Cash Margin From Operations A$461M at March 31

2026-04-23 22:14; UTC

Uždarbis

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

2026-04-23 22:13; UTC

Uždarbis

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

2026-04-23 22:12; UTC

Uždarbis

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

2026-04-23 22:12; UTC

Uždarbis

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

2026-04-23 22:11; UTC

Uždarbis

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

2026-04-23 22:10; UTC

Uždarbis

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

2026-04-23 22:09; UTC

Uždarbis

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

2026-04-23 22:08; UTC

Uždarbis

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

2026-04-23 22:04; UTC

Uždarbis

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

2026-04-23 21:56; UTC

Rinkos pokalbiai

Uždarbis

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

2026-04-23 21:48; UTC

Įsigijimai, susijungimai, perėmimai

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

2026-04-23 21:27; UTC

Uždarbis

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

2026-04-23 21:25; UTC

Uždarbis

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

2026-04-23 21:24; UTC

Uždarbis

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

2026-04-23 21:24; UTC

Uždarbis

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

2026-04-23 21:21; UTC

Uždarbis

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

2026-04-23 21:21; UTC

Uždarbis

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

2026-04-23 21:18; UTC

Uždarbis

Intel Stock Soars on Strong Earnings and Strong Outlook -- Barrons.com

2026-04-23 21:17; UTC

Uždarbis

Intel CEO: Foundry Business Remains a Long Journey

Akcijų palyginimas

Kainos pokytis

Zai Lab Ltd ADR Prognozė

Kainos tikslas

By TipRanks

54.22% į viršų

12 mėnesių prognozė

Vidutinis 35.27 USD 54.22%

Aukščiausias 47 USD

Žemiausias 21.8 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Zai Lab Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Zai Lab Ltd ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

28.13 / 31.12Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.